MM_Logo-cmyk.png
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients
July 27, 2021 02:00 ET | MeMed
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 PatientsMeMed COVID-19 Severity reads the immune-system in real time to accurately determine whether...
MM_Logo-cmyk.png
MeMed Key® Wins Red Dot Award for High Design Quality
April 22, 2021 07:00 ET | MeMed
                                                MeMed Key® Wins Red Dot Award for High Design Quality HAIFA, April 22, 2021- frog, a leading global design and strategy consultancy, part of...
MM_Logo-cmyk.png
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response
April 13, 2021 07:00 ET | MeMed
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response HAIFA, Israel, April 13, 2021 – MeMed, a leader in...
MM_Logo-cmyk.png
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.
January 12, 2021 07:00 ET | MeMed
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S. Troy brings 20 years of top-flight sales and commercial experience as MeMed expands into the U.S....
MM_Logo-cmyk.png
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors
December 16, 2020 07:12 ET | MeMed
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors HAIFA, Israel, December 16, 2020 – MeMed, a leader in host immune response-based solutions, today announced that Chris Hibberd...
MM_Logo-cmyk.png
MeMed Selected to Present at BARDA Industry Day 2020
October 26, 2020 07:00 ET | MeMed
MeMed Selected to Present at BARDA Industry Day 2020 Dr. Eran Eden to Give Lightning Talk on October 27 on MeMed’s Advanced Host-Immune Response Technology HAIFA, Israel, October 26, 2020 – MeMed™,...
MM_Logo-cmyk.png
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 08, 2020 07:00 ET | MeMed
  DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...
MM_Logo-cmyk.png
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案
September 08, 2020 02:02 ET | MeMed
  DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案                                                                                                                                         ...
MM_Logo-cmyk.png
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti
September 08, 2020 01:30 ET | MeMed
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti Accordo di licenza per...
MM_Logo-cmyk.png
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 08, 2020 01:30 ET | MeMed
 DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...